UBS Group’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $206K | Sell |
|
|||||
|
2025
Q1 | $119K | Buy |
|
|||||
|
2024
Q4 | $111K | Buy |
|
|||||
|
2024
Q3 | $155K | Buy |
|
|||||
|
2024
Q2 | $76.2K | Sell |
|
|||||
|
2024
Q1 | $207K | Sell |
|
|||||
|
2023
Q4 | $158K | Buy |
|
|||||
|
2023
Q3 | $62.5K | Sell |
|
|||||
|
2023
Q2 | $86.1K | Buy |
|
|||||
|
2023
Q1 | $4.88K | Sell |
|
|||||
|
2022
Q4 | $12.3K | Buy |
|
|||||
|
2022
Q3 | $1K | Sell |
|
|||||
|
2022
Q2 | $18K | Buy |
|
|||||
|
2022
Q1 | $1K | Sell |
|
|||||
|
2021
Q4 | $97K | Sell |
|
|||||
|
2021
Q3 | $523K | Buy |
|
|||||
|
2021
Q2 | $13K | Sell |
|
|||||
|
2021
Q1 | $17K | Sell |
|
|||||
|
2020
Q4 | $44K | Buy |
|
|||||
|
2020
Q3 | $1K | Sell |
|
|||||
|
2020
Q2 | $1K | Sell |
|
|||||
|
2020
Q1 | $59K | Sell |
|
|||||
|
2019
Q4 | $139K | Buy |
|
|||||
|
2019
Q3 | $82K | Buy |
|
|||||
|
2019
Q2 | $26K | Buy |
|
|||||
|
2019
Q1 | $15K | Sell |
|
|||||
|
2018
Q4 | $49K | Sell |
|
|||||
|
2018
Q3 | $162K | Buy |
|
|||||
|
2018
Q2 | $58K | Buy |
|
|||||
|
2018
Q1 | $40K | Buy |
|
|||||
|
2017
Q4 | $18K | Buy |
|
|||||
|
2017
Q3 | $1K | Sell |
|
|||||
|
2017
Q2 | $2K | Buy |
|
|||||
|
2017
Q1 | $1K | Sell |
|
|||||
|
2016
Q4 | $27K | Buy |
|
|||||
|
2016
Q3 | $7K | Buy |
|
|||||
|
2016
Q2 | $4K | Sell |
|
|||||
|
2016
Q1 | $7K | Sell |
|
|||||
|
2015
Q4 | $18K | Buy |
|
|||||
|
2015
Q3 | $8K | Buy |
|
|||||
|
2015
Q2 | $6K | Sell |
|
|||||
|
2015
Q1 | $13K | Sell |
|
|||||
|
2014
Q4 | $19K | Buy |
|